Hyphens Pharma International (SGX:1J5) EBIT : S$11.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Hyphens Pharma International EBIT?

Hyphens Pharma International's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was S$4.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was S$11.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hyphens Pharma International's annualized ROC % for the quarter that ended in Jun. 2023 was 17.70%. Hyphens Pharma International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 45.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hyphens Pharma International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 18.44%.

Hyphens Pharma International EBIT Historical Data

The historical data trend for Hyphens Pharma International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyphens Pharma International EBIT Chart

Hyphens Pharma International Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

7.13

8.13

7.22

8.35

14.53

Hyphens Pharma International Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT	Get a 7-Day Free Trial										5.28	3.07	7.90	6.63	4.34

Competitive Comparison of Hyphens Pharma International's EBIT

For the Pharmaceutical Retailers subindustry, Hyphens Pharma International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyphens Pharma International's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Hyphens Pharma International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hyphens Pharma International's EV-to-EBIT falls into.

Hyphens Pharma International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$11.0 Mil.

Hyphens Pharma International (SGX:1J5) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hyphens Pharma International's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	8.708 * ( 1 - 15.79% )	/	( (40.255	+	42.592)	/ 2 )
=	7.3330068	/	41.4235
=	17.70 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	114.469	-	37.734	-	( 36.48	-	max(0, 40.074	-	89.652	+	36.48	))
=	40.255

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	115.331	-	39.612	-	( 33.127	-	max(0, 41.486	-	91.151	+	33.127	))
=	42.592

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Hyphens Pharma International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	8.682	/	( ( (3.017 + max(15.097, 0))	+	(2.171 + max(17.946, 0)) )	/	2 )
=	8.682	/	( ( 18.114	+	20.117 )	/	2 )
=	8.682	/	19.1155
=	45.42 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(30.119	+	21.26	+	1.452)	-	(37.734	+	0	+	0)
=	15.097

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(31.815	+	23.807	+	1.936)	-	(39.612	+	0	+	-7.105427357601E-15)
=	17.946

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hyphens Pharma International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	10.974	/	59.519
	=	18.44 %

Hyphens Pharma International EBIT Related Terms

Thank you for viewing the detailed overview of Hyphens Pharma International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyphens Pharma International (SGX:1J5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Hyphens Pharma International Ltd (SGX:1J5) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Tai Seng Street, Level 4, Singapore, SGP, 534138

Website

https://www.hyphensgroup.com

Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include Specialty Pharma Principals segment; Proprietary Brands segment and Medical Hypermart and Digital segment. Specialty pharma principals segment engages in the business of selling and marketing specialty pharmaceutical products. Proprietary Brands segment develops, markets and sells own proprietary range of dermatological products and health supplement products through Hyphens and Ocean Health Singapore. Medical Hypermart and Digital is engaged in the wholesale of pharmaceuticals and medical supplies in Singapore through Pan-Malayan.

Hyphens Pharma International (SGX:1J5) Headlines

No Headlines